OGN
Organon & Co. Health Care Pharmaceutical Preparations Russell 3000
$13.84Close
$3.6BMarket cap
$5.68 – $13.8452-week range
Nov 9, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 90 · stronger than 90% of stocks over 12 months
- Near its high at its 52-week high
Cautions
- Earnings shrinking EPS −2% year on year
- Results soon Nov 9, 2026, in 8 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 0.7%
price change
1mo
up 1.0%
price change
12-month return
up 112%
market up 11% ·
its own up 109%
F-score
5 / 9
Mixed
Altman Z
1.20
Elevated risk
P/E
19.3×
price / earnings
PEG
—
P/E / EPS growth
P/B
4.8×
price / book
Earnings yield
up 8.0%
EBIT / enterprise value
Cheaper than
73%
of the market · cheap
Revenue growth
down 3%
year on year
EPS growth
down 2%
latest quarter · +26 pts
Sales growth
down 2%
latest quarter · +1 pts
ROE
up 31%
return on equity
Free cash margin
up 9%
$538.0M FCF
D/E
11.47
long-term debt / equity
Net debt / EBITDA
8.7×
Interest cover
1.8×EBIT / interest
Piotroski tests
- profitability slipped from last year
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
Trade setup
ATR%
0.3%
$0.04 a day · 2×ATR $13.76
RS
90 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
1.50
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Interest is covered, but thinly Earnings before interest cover the interest bill 1.8 times, leaving little room if profits fall.
- Heavily indebted Net debt is 8.7 times EBITDA — roughly 9 years of earnings before interest, tax and depreciation to repay borrowings in full.
- Gross margin narrowing Gross margin fell from 58.0% to 53.3%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 2.9% over the year, from $6.4B to $6.2B.
Last reported
Apr 30, 2026
Financials
- Gross 53%
- Net 3%
- Free cash 9%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.5B | $6.3B | $6.2B | $6.3B | $6.4B | $6.2B |
| Gross margin | 68% | 62% | 63% | 60% | 58% | 53% |
| Net income | $2.2B | $1.4B | $917.0M | $1.0B | $864.0M | $187.0M |
| Net margin | 33% | 21% | 15% | 16% | 13% | 3% |
| Earnings per share | $8.52 | $5.31 | $3.59 | $3.99 | $3.33 | $0.72 |
| Free cash flow | $2.0B | $2.0B | $662.0M | $548.0M | $764.0M | $538.0M |
| Free cash margin | 31% | 31% | 11% | 9% | 12% | 9% |
| Cash | $12.0M | $737.0M | $706.0M | $693.0M | $675.0M | $574.0M |
| Long-term debt | $0 | $9.1B | $8.9B | $8.8B | $8.9B | $8.6B |
| Shareholders' equity | $5.5B | -$1.5B | -$892.0M | -$70.0M | $472.0M | $752.0M |
| Shares outstanding | — | 253.55m | 254.37m | 255.63m | 257.80m | 260.32m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 30, 2026 | Quarterly ↗ | Sep 30, 2026 | 30d |
| Jul 31, 2026 | Quarterly ↗ | Jun 30, 2026 | 31d |
| May 4, 2026 | Quarterly ↗ | Mar 31, 2026 | 34d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 2, 2025 | Quarterly ↗ | Mar 31, 2025 | 32d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 1, 2024 | Quarterly ↗ | Sep 30, 2024 | 32d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 3, 2024 | Quarterly ↗ | Mar 31, 2024 | 33d |
| Feb 26, 2024 | Annual ↗ | Dec 31, 2023 | 57d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 30, 2026 | Regulation FD ↗ |
| Jul 31, 2026 | Regulation FD ↗ |
| Jul 23, 2026 | Shareholder vote ↗ |
| Jul 17, 2026 | Other events ↗ |
| Jun 11, 2026 | Director or officer change · Shareholder vote ↗ |
| Apr 30, 2026 | Results ↗ |
| Apr 27, 2026 | Material agreement · Director or officer change · Regulation FD ↗ |
| Feb 20, 2026 | Other events ↗ |
| Feb 12, 2026 | Results · Regulation FD ↗ |
| Nov 10, 2025 | Results · Regulation FD ↗ |
| Nov 7, 2025 | Director or officer change ↗ |
| Oct 27, 2025 | Director or officer change · Other events ↗ |